公开(公告)号：US20240352002A1

公开(公告)日：2024-10-24

申请号：US18035262

申请日：2021-11-18

Applicant: Curasen Therapeutics, Inc.

Inventor： Jiaxin Yu ,  David Scott Carter ,  Anthony P. Ford ,  Wei Chen

IPC: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

CPC classification number: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof. Further disclosed herein is a compound according to Formula (II) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

公开(公告)号：US20240351988A1

公开(公告)日：2024-10-24

申请号：US18685378

申请日：2022-09-14

Applicant: Allianthera (Suzhou) Biopharmaceutical Co., Ltd. ,  Allianthera Boston Inc.

Inventor： Jinshan Chen ,  Rajiv Chopra ,  Jiamin Gu

IPC: C07D237/24 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D237/24 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K39/3955 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed herein.

公开(公告)号：US20240336593A1

公开(公告)日：2024-10-10

申请号：US18043962

申请日：2021-09-03

Applicant: lnnovStoneTherapeutics Limited

Inventor： Qun Dang ,  Hanyu Yang ,  Pan Li ,  Chunhua Jiang ,  Zhou Yin ,  Jianbin Ma ,  Xiaodan Fu ,  Xin Cai

IPC: C07D401/14 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D513/04

CPC classification number: C07D401/14 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D513/04

Abstract: The present disclosure provides a compound having a novel structure as a PRMT5 inhibitor, a method for preparing the compound, and use thereof in the treatment of a disease mediated by a PRMT5 inhibitor. Experiments have shown that these compounds have a strong inhibitory effect on PRMT5, and can be used as promising candidate compounds for treatment of diseases mediated by PRMT5 inhibitors. In addition, a specific synthetic method is developed in the present disclosure, which has a simple process and convenient operation, and is beneficial to industrial mass production and application.

公开(公告)号：US20240335454A1

公开(公告)日：2024-10-10

申请号：US18742438

申请日：2024-06-13

Applicant: Delix Therapeutics, Inc.

Inventor： Noel Aaron POWELL ,  Milan CHYTIL

IPC: A61K31/55 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61P25/24 ,  A61P25/28 ,  C07D487/04

CPC classification number: A61K31/55 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4866 ,  A61P25/24 ,  A61P25/28 ,  C07D487/04

Abstract: Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and/or plasticity, such as neurological diseases and disorders, with phenoxy or benzyloxy substituted psychoplastogens.

公开(公告)号：US20240335431A1

公开(公告)日：2024-10-10

申请号：US18613180

申请日：2024-03-22

Applicant: Acerta Pharma B.V.

Inventor： Stephen ATKINSON ,  Gerjan DE BRUIN ,  Flavia IZZO ,  Chimed JANSEN ,  Olaf KINZEL ,  Martin PACKER ,  Saskia VERKAIK ,  Robin VOETS

IPC: A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04

CPC classification number: A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04

Abstract: Compounds having the structure of Formula (I):




and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and A are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Menin-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20240327351A1

公开(公告)日：2024-10-03

申请号：US18276433

申请日：2022-02-09

Applicant: TRIANA BIOMEDICINES, INC.

Inventor： William J. Greenlee ,  Nicholas Calandra ,  Soumya Ray ,  Arthur F. Kluge

IPC: C07D209/30 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/107 ,  C07D498/10

CPC classification number: C07D209/30 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/107 ,  C07D498/10

Abstract: The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the disclosure. Methods of treating disease and disorders that results from abnormal activity of a target protein in a subject, are also disclosed.

公开(公告)号：US20240325407A1

公开(公告)日：2024-10-03

申请号：US18666388

申请日：2024-05-16

Applicant: ATAI Therapeutics, Inc.

Inventor： Holger WEIS ,  Emeline MAILLET

IPC: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24

CPC classification number: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24

Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

公开(公告)号：US20240317734A1

公开(公告)日：2024-09-26

申请号：US18691877

申请日：2022-09-13

Applicant: MONTELINO THERAPEUTICS, INC.

Inventor： Jenny DESANTIS ,  Roy Joseph VAZ ,  Michela ELEUTERI

IPC: C07D417/14 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  C07D491/08

CPC classification number: C07D417/14 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  C07D491/08

Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.

公开(公告)号：US20240317721A1

公开(公告)日：2024-09-26

申请号：US18571588

申请日：2022-06-22

Applicant: NOVARTIS AG

Inventor： Claudio BOMIO-CONFAGLIA ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Marc GERSPACHER ,  Catherine LEBLANC ,  Fabio LIMA ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Sophie RACINE ,  Pascal RIGOLLIER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Frédéric ZECRI

IPC: C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

CPC classification number: C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

Abstract: The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

公开(公告)号：US20240309030A1

公开(公告)日：2024-09-19

申请号：US18264986

申请日：2022-02-10

Applicant: SHANGHAI SENHUI MEDICINE CO., LTD ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD ,  JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Inventor： Lingjian ZHU ,  Jianyu SHI ,  Changjin JI ,  Bangjie DONG ,  Jian HUANG

IPC: C07F9/553 ,  A61K31/55 ,  A61K31/675 ,  C07D223/16

CPC classification number: C07F9/5535 ,  A61K31/55 ,  A61K31/675 ,  C07D223/16

Abstract: Benzazepine compounds, a preparation method therefor and pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by formula II-1 or formula VIII-1, a pharmaceutical composition containing same, and pharmaceutical use thereof. The benzazepine compounds can be used for treating diseases associated with vasopressin receptors, in particular hypertension, heart disease, etc.